Primary Endpoint
toxicity, rash
DISEASE, BEST, SECONDARY
The median duration of follow up for the entire study group was 30 months (range 14-66) The ORR was 58.3% with 2 patients achieving a VGPR (16.7%) and 5 patients achieving a partial response (41.7%) (Best response by M protein/free light chain.Per trial protocol, 7 patients were initially enrolled and evaluated for response. Amongst these 7 patients 5 responses were seen. Four patients had a best response of PR and 1 patient had a VGPR. Only 5 more patients were recruited prior to closure of the study for a total of 12 patients for evaluation of efficacy. Among these first 7 patients 3 patients ultimately had progressive disease by the end of initial induction therapy, including progression in 2 patients who initially had a response (1 PR and 1 VGPR). One patient discontinued treatment due to toxicity, a grade 3 maculopapular rash felt to be secondary to Ixazomib. By the end of induction only 2 out of the first 7 patients had completed induction therapy and continued to have a response but neither of these patients achieved a VGPR. A swimmer’s plot of these first 7 patients and their response course is depicted in 